William Blair Comments on Pyxis Oncology Q1 Earnings

Pyxis Oncology, Inc. (NASDAQ:PYXS) – Analysts at William Blair issued their Q1 2025 earnings per share estimates for Pyxis Oncology in a report released on Tuesday, March 18th. William Blair analyst A. Hsieh expects that the company will post earnings per share of ($0.32) for the quarter. William Blair has a “Market Perform” rating on the stock. The consensus estimate for Pyxis Oncology’s current full-year earnings is ($1.04) per share. William Blair also issued estimates for Pyxis Oncology’s Q2 2025 earnings at ($0.32) EPS, Q3 2025 earnings at ($0.31) EPS, Q4 2025 earnings at ($0.31) EPS, FY2025 earnings at ($1.26) EPS and FY2026 earnings at ($1.32) EPS.

Pyxis Oncology (NASDAQ:PYXS) last announced its earnings results on Tuesday, March 18th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.33) by $0.01.

A number of other research analysts have also recently weighed in on PYXS. Royal Bank of Canada reaffirmed an “outperform” rating and set a $8.00 price objective on shares of Pyxis Oncology in a research report on Wednesday. HC Wainwright reaffirmed a “buy” rating and set a $5.00 price objective on shares of Pyxis Oncology in a research report on Wednesday. One analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $9.20.

Pyxis Oncology Stock Performance

Shares of NASDAQ:PYXS opened at $1.12 on Friday. Pyxis Oncology has a 52-week low of $0.99 and a 52-week high of $6.18. The stock has a market capitalization of $66.60 million, a price-to-earnings ratio of -1.09 and a beta of 1.11. The stock’s 50-day simple moving average is $1.33 and its two-hundred day simple moving average is $2.38.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in PYXS. Millennium Management LLC lifted its holdings in Pyxis Oncology by 53.8% in the 4th quarter. Millennium Management LLC now owns 2,980,906 shares of the company’s stock worth $4,650,000 after purchasing an additional 1,043,228 shares in the last quarter. Jacobs Levy Equity Management Inc. purchased a new position in Pyxis Oncology in the 3rd quarter worth approximately $1,405,000. Ridgeback Capital Investments L.P. purchased a new position in Pyxis Oncology in the 4th quarter worth approximately $560,000. State Street Corp lifted its holdings in Pyxis Oncology by 28.0% in the 3rd quarter. State Street Corp now owns 951,251 shares of the company’s stock worth $3,491,000 after purchasing an additional 208,344 shares in the last quarter. Finally, OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new position in Pyxis Oncology in the 4th quarter worth approximately $228,000. 39.09% of the stock is owned by hedge funds and other institutional investors.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.